TP53 and lung cancer: Several MDM2 targeted inhibitors that interfere with the interaction of MDM2 with p53 or block MDM2 expression have been developed for the treatment of lung cancer and others, including neuroblastoma, retinoblastoma, leukemia and melanoma [19,84,85,107].